Sie suchten nach: pneumokoknih (Kroatisch - Englisch)

istodobna primjena nije utjecala na preostalih devet pneumokoknih serotipova.
there was no impact of co-administration on the other nine pneumococcal serotypes.

istovremena primjena nije imala utjecaja na preostalih devet pneumokoknih serotipova.
there was no impact of co-administration on the other nine pneumococcal serotypes.

vidjeti dijelove 4.4 i 5.1 za informacije o zaštiti od specifičnih pneumokoknih serotipova.
see sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.

bolesnici u dobi manjoj od 18 godina moraju biti cijepljeni protiv bakterije haemophilus influenzae i pneumokoknih infekcija.
patients less than 18 years of age must be vaccinated against haemophilus influenzae and pneumococcal infections.

liječnik će cijepiti vašu djecu koja su mlađa od 18 godina protiv bakterije haemophilus influenzae i pneumokoknih infekcija sukladno nacionalnim smjernicama o cijepljenju pojedine dobne skupine.
your doctor will administer a vaccine to your child aged less than 18 years against haemophilus influenzae and pneumococcal infections according to the national vaccination recommendations for each age group.

primjena cjepiva synflorix mora biti temeljena na osnovi službenih preporuka koje uzimaju u obzir utjecaj pneumokoknih bolesti u različitim dobnim skupinama kao i varijabilnost epidemiologije u različitim zemljopisnim područjima.
the use of synflorix should be determined on the basis of official recommendations taking into consideration the impact on pneumococcal diseases in different age groups as well as the variability of the epidemiology in different geographical areas.

u djece u dobi između pet i 17 godina, prevenar 13 prouzročio je odgovor koji je bio najmanje podjednako dobar kao u slučaju lijeka prevenar za svih sedam zajedničkih pneumokoknih polisaharida.
in children aged between five and 17 years old, prevenar 13 produced a response that was at least as good as prevenar for all seven s. pneumoniae polysaccharides they share in common.

kod djece i adolescenata u dobi od 6 do 17 godina, incidencija pneumokoknih bolesti je niska, međutim, postoji povećan rizik morbiditeta i mortaliteta kod onih s prisutnim komorbiditetom.
in children and adolescents aged 6 to 17 years, the incidence of pneumococcal disease is low, however, there is an increased risk of morbidity and mortality in those with underlying comorbidities.

sličan udio odraslih bolesnika razvio je zaštitne razine anti-pneumokoknih i anti-tetanus protutijela, a titri protutijela bili su slični kod bolesnika liječenih stelarom i u kontrolnih bolesnika.
similar proportions of adult patients developed protective levels of anti-pneumococcal and anti-tetanus antibodies and antibody titers were similar among stelara-treated and control patients.

nema dovoljno dokaza da synflorix pruža zaštitu od pneumokoknih serotipova koji nisu sadržani u cjepivu osim ukriženo reaktivnog serotipa 19a (vidjeti dio 5.1.) ili od netipiziranog haemophilus influenzae.
there is insufficient evidence that synflorix provides protection against pneumococcal serotypes not contained in the vaccine except the cross-reactive serotype 19a (see section 5.1) or against non- typeable haemophilus influenzae.

kod djece sa simptomima akutne upale srednjeg uha u preglednoj studiji u francuskoj procjenjivale su se promjene nazofaringalnog kliconoštva pneumokoknih serotipova nakon uvođenja prevenara (7- valentnog) i nastavno prevenara 13.
in a surveillance study in france in children presenting with acute otitis media, changes in nasopharyngeal (np) carriage of pneumococcal serotypes were evaluated following the introduction of prevenar (7-valent) and subsequently prevenar 13.

deset pneumokoknih serotipova, sadržanih u ovom cjepivu, predstavljaju glavne serotipove uzročnika bolesti u europi, koji pokrivaju oko 56% do 90% invazivne pneumokokne bolesti (ipb) u djece mlađe od 5 godina.
the 10 pneumococcal serotypes included in this vaccine represent the major disease-causing serotypes in europe covering approximately 56% to 90% of invasive pneumococcal disease (ipd) in children <5 years of age.